Loading...
01/10 16:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Earnings call highlights strong year-over-year financial performance, including doubled net revenue and increased prescriptions, indicating market growth. Despite increased expenses, the company reduced its net loss compared to the previous year. Management's optimistic guidance of $14 million sales for 2024 and strategic investments that have doubled patient count further support positive sentiment. Risks like financial sustainability and reliance on pharmacy networks are noted, but the overall narrative is growth-oriented, with the potential for further market expansion.
Net Product Sales (Q4 2023) $1.7 million, up from $796,000 in Q4 2022, reflecting a year-over-year increase due to higher prescription sales through pharmacy service partnerships.
Net Loss (Q4 2023) $2 million or $0.59 per share, compared to $1.8 million or $0.54 per share in Q4 2022.
Net Product Sales (Full Year 2023) $5.2 million, compared to $2.5 million for the year ended December 31, 2022, due to increased prescription sales.
Net Loss (Full Year 2023) $7.8 million or $2.33 per share, compared to a net loss of $8.2 million or $2.62 per share for the year ended December 31, 2022.
Research and Development Expenses (Q4 2023) $27,000, compared to $23,000 for Q4 2022.
Research and Development Expenses (Full Year 2023) Approximately $0.3 million, compared to approximately $0.2 million for the prior year.
Selling, General and Administrative Expenses (Q4 2023) $3.5 million, compared to $2.3 million for Q4 2022, due to higher marketing royalty and Eversana profit sharing costs.
Selling, General and Administrative Expenses (Full Year 2023) $12.2 million, versus approximately $9.6 million for the year ended December 31, 2022.
Total Operating Expenses (Q4 2023) $3.6 million, compared with $2.3 million for the same period of 2022.
Total Operating Expenses (Full Year 2023) $12.6 million, compared with approximately $10.3 million for the full year of 2022.
Cash and Cash Equivalents (As of December 31, 2023) Approximately $4.7 million, expected to fund operations into the fourth quarter of 2024.
Net Revenue for GIMOTI: Evoke Pharma doubled its net revenue for GIMOTI over the last year, reaching approximately $5.2 million in 2023 compared to $2.5 million in 2022.
New Prescriptions Growth: The number of new prescriptions for GIMOTI grew by 86% year-over-year.
Total Prescriptions Dispensed: Total prescriptions dispensed increased by 101% year-over-year.
Projected Revenue for 2024: Evoke aims for a projected net revenue of approximately $14 million in 2024, nearly tripling its 2023 performance.
Market Share Growth: GIMOTI's market share compared to oral metoclopramide showed significant gains throughout 2023, particularly among nurse practitioners and physician assistants.
Impact of GLP-1 Agonists: Increased use of GLP-1 agonists may lead to a rise in gastroparesis cases, potentially expanding the market for GIMOTI.
Pharmacy Services Transition: Evoke transitioned its pharmacy services to ASPN, enhancing distribution capabilities and patient access.
Improved Prescription Fill Rates: With ASPN, there has been a 2% increase in new prescriptions filled and a 12% reduction in patient-initiated abandonment of prescriptions.
Strategic Partnerships: Evoke is partnering with pharmacy organizations to improve prescription fill rates and streamline distribution.
Educational Initiatives: Evoke plans to intensify educational efforts regarding the risks associated with tardive dyskinesia to enhance provider confidence in prescribing GIMOTI.
Regulatory Issues: GIMOTI carries a box warning for tardive dyskinesia (TD), which may deter providers from prescribing it. There is a significant gap in gastroenterologists' understanding of TD, leading to hesitancy in prescribing GIMOTI.
Competitive Pressures: The increasing use of GLP-1 receptor agonists may lead to more patients suffering from gastroparesis, potentially expanding the market for GIMOTI. However, the association of GLP-1s with adverse events like gastroparesis could create competition.
Supply Chain Challenges: Evoke and Eversana faced challenges due to a Change Healthcare outage, which affected providers' ability to check patient eligibility and submit claims, impacting new prescribing.
Economic Factors: The company anticipates higher co-pay expenses and discounting at the beginning of the year due to changes in patient coverage and the need for patients to meet deductibles.
Net Revenue Growth: Projected net revenue of approximately $14 million for 2024, nearly tripling 2023 performance.
Prescription Growth: New prescriptions grew by 86% and total prescriptions dispensed increased by 101% year-over-year.
Strategic Partnerships: Transitioned pharmacy services to ASPN to enhance distribution and patient access.
Market Share: GIMOTI's market share compared to oral metoclopramide showed significant gains throughout 2023.
Patient Access Improvement: Partnership with ASPN Pharmacy to improve fill rates and streamline prescription processes.
Educational Initiatives: Increased communication and education regarding tardive dyskinesia to enhance prescriber confidence.
Financial Outlook: Expecting to increase SG&A expenses as commercialization of GIMOTI progresses.
Cash Flow Projection: Current cash and equivalents of approximately $4.7 million expected to fund operations into Q4 2024.
Market Opportunity: Potential increase in gastroparesis cases due to the rising use of GLP-1 agonists.
Net Product Sales: For the year ended December 31, 2023, net product sales were approximately $5.2 million, compared with approximately $2.5 million for the year ended December 31, 2022.
Net Loss: For the year ended December 31, 2023, the net loss was approximately $7.8 million or $2.33 per share, as compared with a net loss of $8.2 million or $2.62 per share for the year ended December 31, 2022.
Projected Revenue: For 2024, Evoke aims for a projected net revenue of approximately $14 million, nearly tripling their 2023 performance.
Cash and Cash Equivalents: As of December 31, 2023, cash and cash equivalents were approximately $4.7 million.
Operating Expenses: For the year ended December 31, 2023, total operating expenses were approximately $12.6 million, compared with approximately $10.3 million for the full year of 2022.
The earnings call provided positive updates on product development and financial performance, with a 25% revenue increase and improved margins. However, the lack of specific future guidance, regulatory risks, and competitive pressures create uncertainty. The Q&A revealed vague responses regarding competition and Medicaid expansion, adding to the ambiguity. Without clear forward-looking projections, the stock is likely to remain stable, resulting in a neutral sentiment.
The earnings call summary indicates strong financial performance with significant revenue growth and a reduction in net loss. Despite risks in revenue growth and regulatory challenges, the company projects optimistic net revenue guidance for 2025. The Q&A section reveals some uncertainty in the competitive landscape but highlights growth in Medicaid and Medicare scripts. The capital raise and cash runway provide financial stability. Overall, the positive financial outlook and growth potential suggest a positive stock price movement.
Earnings call highlights strong year-over-year financial performance, including doubled net revenue and increased prescriptions, indicating market growth. Despite increased expenses, the company reduced its net loss compared to the previous year. Management's optimistic guidance of $14 million sales for 2024 and strategic investments that have doubled patient count further support positive sentiment. Risks like financial sustainability and reliance on pharmacy networks are noted, but the overall narrative is growth-oriented, with the potential for further market expansion.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
